Literature DB >> 30095396

Penicillin skin testing in the management of penicillin allergy in an outpatient pediatric population.

Christine M Anterasian, Bob Geng.   

Abstract

BACKGROUND: Eight to ten percent of patients believe that they are allergic to penicillin, yet only 10% of those patients have evidence of an immunoglobulin E (IgE) mediated allergy upon penicillin skin testing (PST). In the adult population, a negative PST result is associated with a low risk of immediate reaction on oral challenge, but further studies are needed in the pediatric population.
OBJECTIVE: To calculate the negative predictive value (NPV) of the current skin testing regimen of penicillin, benzylpenicilloyl-polylysine (the major determinant), and ampicillin in a pediatric outpatient population to assess the utility of adding the minor determinant mixture to the skin testing regimen.
METHODS: A retrospective chart review was conducted of all pediatric patients seen in a single-center pediatric allergy/immunology outpatient clinic between January 1, 2010, and March 1, 2016, who underwent PST for presumed penicillin drug allergy.
RESULTS: Only 38% of patients who underwent PST had a drug reaction history consistent with an IgE-mediated reaction. 28.8% of the patients had a positive PST result. The addition of ampicillin to the standard PST regimen of penicillin and benzylpenicilloyl-polylysine identified an additional 4.1% of patients. Two patients (3.2%) reacted on oral challenge with a minor rash. The NPV of the PST regimen was 98%. No significant predictive variables for a positive PST result were identified.
CONCLUSION: Given the high NPV of the current PST regimen, we do not recommend additional testing with the minor determinant mixture. Despite this high NPV, the utility of PST in the low-risk, low-pretest probability outpatient pediatric population was limited, and select patients may be able to proceed directly to oral challenge.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30095396      PMCID: PMC9292462          DOI: 10.2500/aap.2018.39.4138

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.873


  35 in total

1.  Prevalence of skin test reactivity in patients with convincing, vague, and unacceptable histories of penicillin allergy.

Authors:  Rishon H Stember
Journal:  Allergy Asthma Proc       Date:  2005 Jan-Feb       Impact factor: 2.587

2.  Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives.

Authors:  Robert Hermann Grims; Birger Kränke; Werner Aberer
Journal:  Contact Dermatitis       Date:  2006-05       Impact factor: 6.600

3.  Adverse reactions following intravenous penicillin-G relate to degradation of the drug in vitro.

Authors:  K A Neftel; M Wälti; H K Schulthess; J Gubler
Journal:  Klin Wochenschr       Date:  1984-01-02

4.  Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests.

Authors:  C Ponvert; Y Perrin; A Bados-Albiero; M Le Bourgeois; C Karila; C Delacourt; P Scheinmann; J De Blic
Journal:  Pediatr Allergy Immunol       Date:  2011-03-30       Impact factor: 6.377

5.  Results of drug hypersensitivity evaluations in a large group of children and adults.

Authors:  M Rubio; P-J Bousquet; E Gomes; A Romano; P Demoly
Journal:  Clin Exp Allergy       Date:  2011-10-13       Impact factor: 5.018

6.  Penicillin allergy: a study of incidence as reported by patients.

Authors:  J R Kerr
Journal:  Br J Clin Pract       Date:  1994 Jan-Feb

7.  Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization.

Authors:  L M Mendelson; C Ressler; J P Rosen; J E Selcow
Journal:  J Allergy Clin Immunol       Date:  1984-01       Impact factor: 10.793

8.  Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children.

Authors:  Christopher Mill; Marie-Noël Primeau; Elaine Medoff; Christine Lejtenyi; Andrew O'Keefe; Elena Netchiporouk; Alizee Dery; Moshe Ben-Shoshan
Journal:  JAMA Pediatr       Date:  2016-06-06       Impact factor: 16.193

9.  Skin testing and oral penicillin challenge in patients with a history of remote penicillin allergy.

Authors:  Arnon Goldberg; Ronit Confino-Cohen
Journal:  Ann Allergy Asthma Immunol       Date:  2008-01       Impact factor: 6.347

10.  The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge.

Authors:  Jean-Christoph Caubet; Laurent Kaiser; Barbara Lemaître; Benoît Fellay; Alain Gervaix; Philippe A Eigenmann
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

View more
  4 in total

1.  Beta-lactam allergy and drug challenge test in children: a systematic review and meta-analysis.

Authors:  Yasutaka Kuniyoshi; Yasushi Tsujimoto; Masahiro Banno; Shunsuke Taito; Takashi Ariie; Takafumi Kubota; Natsuki Takahashi; Haruka Tokutake
Journal:  Pediatr Res       Date:  2022-04-21       Impact factor: 3.756

2.  Children are not small adults.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2018-07-01       Impact factor: 2.873

3.  Penilloic acid is the chief culprit involved in non-IgE mediated, immediate penicillin-induced hypersensitivity reactions in mice.

Authors:  Dunfang Wang; Jiayin Han; Chen Pan; Chunying Li; Yong Zhao; Suyan Liu; Yushi Zhang; Jingzhuo Tian; Yan Yi; Jingjing Zhu; Chenyue Liu; Yuan Wang; Zhong Xian; Jing Meng; Shasha Qin; Xuan Tang; Fang Wang; Aihua Liang
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

4.  Frequency of severe reactions following penicillin drug provocation tests: A Bayesian meta-analysis.

Authors:  António Cardoso-Fernandes; Kimberly G Blumenthal; Anca Mirela Chiriac; Isabel Tarrio; David Afonso-João; Luís Delgado; João Almeida Fonseca; Luís Filipe Azevedo; Bernardo Sousa-Pinto
Journal:  Clin Transl Allergy       Date:  2021-06       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.